Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio Submits NDA for Iclaprim|
June 14, 2018
|Motif Bio Announces New Iclaprim Data Presented at ASM Microbe 2018|
June 11, 2018
|Motif Bio to present at Jefferies Global Healthcare Conference in New York|
May 31, 2018